rolled trial (RCT)
• Severe COVID-19 infections
• 18–85 years of age
• Elevated serum IL-6
•  N = 94 standard therapy + tocilizumab
•  N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once
• Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocili